Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline
about
Crosstalk between the heart and peripheral organs in heart failureHeart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnosticsOxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosisNutritional and anti-inflammatory interventions in chronic heart failure.Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.Allopurinol reduces antigen-specific and polyclonal activation of human T cells.Heart failure in sub-Saharan Africa.How can we cure a heart "in flame"? A translational view on inflammation in heart failure.Cardiomyopathies and myocardial disorders in Africa: present status and the way forwardImmunological mechanisms of pentoxifylline in chronic heart failure.Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support.Central nervous system circuits modified in heart failure: pathophysiology and therapeutic implications.Pentoxifylline in heart failure: a meta-analysis of clinical trials.Innate immunity and the failing heart: the cytokine hypothesis revisited.Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms.C-reactive protein predicts response to pentoxifylline in patients with idiopathic dilated cardiomyopathy.Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets.
P2860
Q26766491-A43DA65F-A5C5-4AF2-B2E6-FCB583682D16Q27015261-A28F8881-22A2-49C7-9D6A-287055AF64C5Q28084150-8328FE33-5284-46D8-923B-186C0F27E407Q33880185-A1614502-D38B-4C72-9838-9FB2A6251A36Q34563378-72E5F785-6A73-449E-8630-8DD156F4C8DEQ35604952-B5167F24-CB03-4ACD-AD78-9B7EA9870EBFQ36250232-5EE6368E-18E7-4AF0-B993-8D489BBA2074Q36928528-41DCC181-994F-4D89-BD1C-92509E88BFF4Q37004826-75EBC36F-2DC0-44F6-94ED-FEDE1674CACAQ37041843-6E3C09C0-CE0F-4F5C-89E2-EADE7D018830Q37377105-EB498EEB-C31F-43A3-BC0E-9427AB497EC4Q37700358-3FAFDAC1-2788-4CCA-816F-435F702880B8Q38191484-8918FD46-4775-4ACB-BB6E-F5BEE829776CQ38206557-499756FF-CD96-4BA4-B0DA-7B27080027EBQ38393039-32E81988-B191-438F-B34E-6C3F3792B1F7Q44776909-0747EC0C-8DA4-4F49-BFC9-EB2B05C5B962Q45149750-D656B44D-34AA-4ACF-BDB3-FE230559C33FQ47756011-97F3E5DB-448C-44BA-B681-5F18C0579336
P2860
Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Reduction in Fas/APO-1 plasma ...... hy treated with pentoxifylline
@ast
Reduction in Fas/APO-1 plasma ...... hy treated with pentoxifylline
@en
type
label
Reduction in Fas/APO-1 plasma ...... hy treated with pentoxifylline
@ast
Reduction in Fas/APO-1 plasma ...... hy treated with pentoxifylline
@en
prefLabel
Reduction in Fas/APO-1 plasma ...... hy treated with pentoxifylline
@ast
Reduction in Fas/APO-1 plasma ...... hy treated with pentoxifylline
@en
P2093
P2860
P356
P1433
P1476
Reduction in Fas/APO-1 plasma ...... hy treated with pentoxifylline
@en
P2093
P2860
P304
P356
10.1136/HEART.84.4.438
P407
P577
2000-10-01T00:00:00Z